Watch PMCB. Know when insiders buy.
One email the day a filing lands. Free.
PMCB
PharmaCyte Biotech, Inc.
0.44
−0.02 −3.37%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.7MP/E —DIV YIELD —FCF YIELD —REV TTM $0NET INCOME −$16.1MNET CASH $17.5M52W 0.38 – 1.22SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2027 · Jul 31 | $0 | — | — | −$1M | −$5.1M | — | -0.54 | −$781K | — | — | Sep 14 |
| Q4 2026 · Apr 30derived | $0 | — | — | −$2.5M | −$4.4M | −137.4% | -0.36 | −$1.4M | — | — | Jul 29 |
| Q3 2026 · Jan 31 | $0 | — | — | −$2.1M | $747K | — | -0.17 | −$787K | — | — | Mar 17 |
| Q2 2026 · Oct 31 | $0 | — | — | −$1.4M | −$7.4M | — | -1.24 | −$980K | — | — | Mar 17 |
| Q1 2026 · Jul 31 | $0 | — | — | −$848K | −$8.4M | −135.7% | -1.23 | −$2M | — | — | Sep 14 |
| Q4 2025 · Apr 30derived | $0 | — | — | −$1M | $11.7M | +772.5% | 1.52 | −$1M | — | — | Jul 29 |
| Q3 2025 · Jan 31 | $0 | — | — | −$960K | −$3M | — | -0.44 | −$510K | — | — | Mar 17 |
| Q2 2025 · Oct 31 | $0 | — | — | −$1.1M | −$1.5M | −152.7% | -0.39 | −$1.1M | — | — | Mar 17 |
| Q1 2025 · Jul 31 | $0 | — | — | −$1.3M | $23.4M | — | 1.90 | −$373K | — | — | Mar 17 |
| Q4 2024 · Apr 30derived | $0 | — | — | −$3.2M | $1.3M | — | -0.33 | −$333K | — | — | Aug 11 |
| Q3 2024 · Jan 31 | $0 | — | — | −$1.9M | −$620K | — | -0.65 | −$177K | — | — | Mar 17 |
| Q2 2024 · Oct 31 | $0 | — | — | −$1.4M | $2.8M | — | -0.26 | −$2M | — | — | Mar 17 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Apr 30 | $0 | — | −$6.9M | −$19.4M | — | -2.77 | −$5.2M | — | — | $402K | — |
| FY2025 · to Apr 30 | $0 | — | −$4.4M | $30.7M | — | 3.19 | −$3M | — | — | $2.5M | — |
| FY2024 · to Apr 30 | $0 | — | −$8.5M | $334K | — | -1.80 | −$2.2M | — | — | $28.2M | — |
| FY2023 · to Apr 30 | $0 | — | −$6.5M | −$4.3M | — | -0.22 | −$3.8M | — | — | $13.6M | — |
| FY2022 · to Apr 30 | $0 | — | −$4.4M | −$4.2M | — | -0.27 | −$4.1M | — | — | $0 | — |
| FY2021 · to Apr 30 | $0 | — | −$3.6M | −$3.6M | — | -2.45 | −$3.3M | — | — | — | — |
Every number comes from PharmaCyte Biotech, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.